Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities (2010 - 2025)

Rigel Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $122.1 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 1.17% year-over-year to $122.1 million; the TTM figure through Dec 2025 stood at $122.1 million (up 1.17% YoY), while the FY2025 annual figure was $122.1 million, up 1.17% from the prior year.
• Total Non-Current Liabilities was $122.1 million for Q4 2025 at Rigel Pharmaceuticals, down from $152.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $152.4 million in Q1 2025 to a low of $80.2 million in Q1 2021.
• Historically, Total Non-Current Liabilities has averaged $103.8 million across 5 years, with a median of $105.7 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities jumped 33.91% in 2021, then slipped 0.55% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $84.2 million in 2021, then rose by 25.41% to $105.6 million in 2022, then climbed by 0.28% to $105.9 million in 2023, then advanced by 13.96% to $120.7 million in 2024, then advanced by 1.17% to $122.1 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $122.1 million (Q4 2025), $152.4 million (Q1 2025), and $120.7 million (Q4 2024), per Business Quant data.